Open an account

Contineum Therapeutics

CTNM · NASDAQ

$8.46+$1.02 (+13.71%)TodayMarket closed ·
Prev close $7.44

About CTNM

Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company is headquartered in San Diego, California and currently employs 51 full-time employees. The company went IPO on 2024-04-05. The company is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The firm is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.

Employees
51
Headquarters
San Diego, California
Listed
Apr 5, 2024
Sector
Health Care
Industry
Pharmaceuticals
Website
contineum-tx.com

CTNM key statistics

Market cap
318.27M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.36M
Volume
2.20M
Open price
$7.38
High today
$8.70
Low today
$7.15
52 Week high
$17.79
52 Week low
$6.73

Contineum Therapeutics (CTNM) at a glance

As of Oct 20, 2026, Contineum Therapeutics (CTNM) shares are priced at $8.46, giving the company a market cap of 318.27M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $7.15 and $8.70. The current price is 18.4% above the day's low and 2.8% below its high.

Volume so far is 2.20M shares, above the average of 1.36M shares a day.

Over the past year Contineum Therapeutics has ranged from $6.73 to $17.79, and now sits 16% of the way up that range.

Contineum Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.40 per share against an estimate of -$0.4607.

The average analyst price target is $22.44, 165.2% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 4 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 9 analystsAvg $22.44
Low
$17.17
Now
$8.46
High
$29.40

CTNM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 13.6% on average.

  1. Q3 FY24: reported -$0.40 per share against an estimate of -$0.4182
  2. Q4 FY24: reported -$0.56 per share against an estimate of -$0.4366
  3. Q1 FY25: reported -$0.62 per share against an estimate of -$0.5763
  4. Q2 FY25: reported -$0.62 per share against an estimate of -$0.4488
  5. Q3 FY25: reported -$0.45 per share against an estimate of -$0.4934
  6. Q4 FY25: reported -$0.49 per share against an estimate of -$0.4138
  7. Q1 FY26: reported -$0.39 per share against an estimate of -$0.5421
  8. Q2 FY26: reported -$0.40 per share against an estimate of -$0.4607

CTNM news

  • Vandana Singh

    Why Is Contineum Therapeutics Stock Falling Monday?

  • Avi Kapoor

    Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday

  • Vandana Singh

    Johnson & Johnson Partner Contineum Slides as Depression Drug Fails

  • Press releaseBusiness Wire

    Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder

  • Press releaseBusiness Wire

    Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Press releaseBusiness Wire

    Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones

  • Press releaseBusiness Wire

    Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry

Similar companies

Companies in the same industry as Contineum Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.